Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene.

Henlius claims win for PD-1 drug in small cell lung cancer

China's Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive sta

Immuno-oncology latecomer GSK shows off PD-1 drug data

BMS and Nektar to pair Opdivo with natural killer cell drug

BMS and Nektar's combination latest in frenzied immunotherapy field

Promise for combination approach to cancer

As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.